Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Journals » International Journal of Child Health and Human Development » Volume 4 Issue 2 Articles » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Exploring Cities and Countries of the World. Volume 1
$250.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Bestsellers
01.Factors Associated with Receipt of Palivizumab among Inner-city Infants
02.Oral Paracetamol (Acetaminophen) with Codeine for Postoperative Pain in Adults
03.Determinants of Sleep Duration and Sleep Quality: Gender Differences, Coping and Health Outcome
04.Interventions for Treating Obesity in Children
05.Sleep and Parenting Styles in Preschool Children in Turkey
06.What Do You Do When No Health and Social Agency Wants to Care for You?
Notifications more
NotificationsNotify me of updates to Factors Associated with Receipt of Palivizumab among Inner-city Infants
Tell A Friend
 
Tell someone you know about this product.
Factors Associated with Receipt of Palivizumab among Inner-city Infants $43.00
Authors:  David Wood, Katryne Lukens-Bull, Kristi Stowers, Mark Hudak and William Livingood
Abstract:
Objective: To determine rate of receipt of palivizumab and factors associated with receipt among poor, inner-city, ex-premature infants. Study Design: Infants from an urban neonatal intensive care unit (NICU) who qualify for palivizumab (by AAP criteria) were prospectively followed through the infantís first RSV season. Parent interviews were conducted at the end of the season to identify factors associated with receipt of palivizumab. Structured provider record reviews assessed receipt of palivizumab. Results: High receipt of palivizumab (34-100% of recommended number of doses) was associated with the following factors: 1) infant was < 3 months of age at the start of the RSV season (OR = 4.32; 95% CI = 1.65, 11.34); 2) a formal development assessment was conducted by the primary care pediatrician by 6 months of age (OR = 3.71; 95% CI = 1.4, 9.83); and 3) the mother reported no emergency room visit by the infant during the RSV season (OR = 3.02; 95% CI = 1.09, 8.42). Conclusions: Receipt of palivizumab for inner-city infants was very low. Prospective identification of infants at risk of not receiving palivizumab may be possible. More organized follow-up of inner-city, high-risk newborns is needed. 


Available Options:
Version:
Special Focus Titles
01.Peter Singerís Ethics: A Critical Appraisal
02.Sexism: Past, Present and Future Perspectives
03.Body and Politics: Elite Disability Sport in China
04.Childhood and Adolescence: Tribute to Emanuel Chigier, 1928-2017
05.Renal Replacement Therapy: Controversies and Future Trends
06.Food-Drug Interactions: Pharmacokinetics, Prevention and Potential Side Effects
07.Terrorism and Violence in Islamic History and Theological Responses to the Arguments of Terrorists
08.International Event Management: Bridging the Gap between Theory and Practice
09.The Sino-Indian Border War and the Foreign Policies of China and India (1950-1965)
10.Tsunamis: Detection, Risk Assessment and Crisis Management
11.Sediment Watch: Monitoring, Ecological Risk Assessment and Environmental Management
12.Self-Regulated Learners: Strategies, Performance, and Individual Differences

Nova Science Publishers
© Copyright 2004 - 2018

Factors Associated with Receipt of Palivizumab among Inner-city Infants